Anika Therapeutics (ANIK) Accounts Payables (2010 - 2026)

Anika Therapeutics (ANIK) has reported Accounts Payables for 17 consecutive years, with $6.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 30.71% year-over-year to $6.2 million in Q2 2026; TTM through Jun 2026 was $6.2 million, a 30.71% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 7.55% from the prior year.
• Accounts Payables was $6.2 million for Q2 2026 at Anika Therapeutics, down from $6.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $10.0 million in Q1 2024 and troughed at $4.7 million in Q3 2025.
• A 5-year average of $7.2 million and a median of $7.1 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables plunged 52.26% in 2025 and jumped 30.71% in 2026, its largest moves.
• Over 5 years, Accounts Payables stood at $9.1 million in 2022, then sank by 31.74% to $6.2 million in 2023, then slipped by 9.32% to $5.6 million in 2024, then advanced by 7.55% to $6.0 million in 2025, then increased by 3.23% to $6.2 million in 2026.
• The last three Accounts Payables figures came in at $6.2 million (Q2 2026), $6.3 million (Q1 2026), and $6.0 million (Q4 2025), per Business Quant data.